Declining sales of Prevnar have urged Pfizer to seek compensation elsewhere, including a vaccine against Group B streptococcus.
BiondVax secured a €20 million loan from the European Investment Bank to advance its universal flu vaccine candidate.
CAR-T and TCR therapies have seen a whirlwind few years. Is 2017 set to be the year we see a CAR-T therapy approved? On a mission to find out, we sat down with…
Florida lawmakers are urging the Army to pump the brakes on its exclusive vaccine license to Sanofi.
Scientists at the University of Maryland, hoping to fill the hepatitis vaccine void, have secured funding from the NIH to work on a new candidate.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
A new U.S. study shows that Merck's Ebola vaccine rVSV-ZEBOV offers protection that can last for at least a year.
The Radboud University Medical Center in the Netherlands, the Instituto de Medicina Molecular Lisboa in Portugal, and PATH are collaborating on a human trial…
Bharat Biotech has initiated a phase 1 trial of its Chikungunya vaccine, while Themis started a phase 2 of its own candidate.
Bexsero has been helping drive revenue growth for GSK, but now, with an EU approval, Pfizer’s Trumenba is set to challenge it in that lucrative market.
Congolese officials have given initial approval to the use of Merck’s as-yet-unlicensed Ebola shot to combat a local outbreak.
A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to…